Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Last Updated: Monday, December 9, 2024

Researchers evaluated data from 742 patients with HER2- breast cancer to assess clinical and molecular differences among HR+ HER2- MammaPrint high-risk 1 (MP-H1), HR+ HER2- MammaPrint very high-risk high-2 (MP-H2), triple-negative MP-H1, and triple-negative MP-H2 cancers. The results showed similar transcriptional and clinical features between HR+ HER2- MP-H2 cancers and triple negative MP-H2 breast cancers. The researchers concluded that these subtypes could benefit from similar treatment strategies.

Clinical Cancer Research

Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Frontiers in Immunology

Advances in Trop-2 targeted antibody-drug conjugates for breast cancer: Mechanisms, clinical applications, and future directions

Cureus

Dormancy leading to late recurrence in breast cancer: A case of hormone receptor-positive supraclavicular metastasis 10 years after the initial treatment

Therapeutic Advances in Medical Oncology

Everolimus treatment in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative advanced breast cancer and a predictive model for its efficacy: A multicenter real-world study

Real-world treatment patterns and outcomes in patients with HR+/HER2- metastatic breast cancer treated with chemotherapy in the United States

Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis

Oncology Letters

First-line endocrine therapy for hormone receptor positive and HER 2 negative metastatic breast cancer: A Bayesian network meta analysis

HR+ HER2- Breast Cancer Resource Center

Hormone receptor positive HER2-negative/MammaPrint high-2 breast cancers closely resemble triple negative breast cancers

Clinical Cancer Research